These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Missense mutations in fumarate hydratase in multiple cutaneous and uterine leiomyomatosis and renal cell cancer. Alam NA; Olpin S; Rowan A; Kelsell D; Leigh IM; Tomlinson IP; Weaver T J Mol Diagn; 2005 Oct; 7(4):437-43. PubMed ID: 16237213 [TBL] [Abstract][Full Text] [Related]
13. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Castro-Vega LJ; Buffet A; De Cubas AA; Cascón A; Menara M; Khalifa E; Amar L; Azriel S; Bourdeau I; Chabre O; Currás-Freixes M; Franco-Vidal V; Guillaud-Bataille M; Simian C; Morin A; Letón R; Gómez-Graña A; Pollard PJ; Rustin P; Robledo M; Favier J; Gimenez-Roqueplo AP Hum Mol Genet; 2014 May; 23(9):2440-6. PubMed ID: 24334767 [TBL] [Abstract][Full Text] [Related]
14. Familial multiple cutaneous and uterine leiomyomas associated with papillary renal cell cancer. Chan I; Wong T; Martinez-Mir A; Christiano AM; McGrath JA Clin Exp Dermatol; 2005 Jan; 30(1):75-8. PubMed ID: 15663510 [TBL] [Abstract][Full Text] [Related]
15. Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers. Zuhlke KA; Madeoy JJ; Beebe-Dimmer J; White KA; Griffin A; Lange EM; Gruber SB; Ostrander EA; Cooney KA Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5975-80. PubMed ID: 15447980 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer. Hu N; Wang C; Han XY; He LJ; Tang ZZ; Giffen C; Emmert-Buck MR; Goldstein AM; Taylor PR Oncogene; 2004 Jan; 23(3):852-8. PubMed ID: 14647438 [TBL] [Abstract][Full Text] [Related]
17. Mutation screening of fumarate hydratase by multiplex ligation-dependent probe amplification: detection of exonic deletion in a patient with leiomyomatosis and renal cell cancer. Ahvenainen T; Lehtonen HJ; Lehtonen R; Vahteristo P; Aittomäki K; Baynam G; Dommering C; Eng C; Gruber SB; Grönberg H; Harvima R; Herva R; Hietala M; Kujala M; Kääriäinen H; Sunde L; Vierimaa O; Pollard PJ; Tomlinson IP; Björck E; Aaltonen LA; Launonen V Cancer Genet Cytogenet; 2008 Jun; 183(2):83-8. PubMed ID: 18503824 [TBL] [Abstract][Full Text] [Related]
18. Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Lehtonen R; Kiuru M; Vanharanta S; Sjöberg J; Aaltonen LM; Aittomäki K; Arola J; Butzow R; Eng C; Husgafvel-Pursiainen K; Isola J; Järvinen H; Koivisto P; Mecklin JP; Peltomäki P; Salovaara R; Wasenius VM; Karhu A; Launonen V; Nupponen NN; Aaltonen LA Am J Pathol; 2004 Jan; 164(1):17-22. PubMed ID: 14695314 [TBL] [Abstract][Full Text] [Related]
19. Evidence for a founder effect of the germline fumarate hydratase gene mutation R58P causing hereditary leiomyomatosis and renal cell cancer (HLRCC). Heinritz W; Paasch U; Sticherling M; Wittekind C; Simon JC; Froster UG; Renner R Ann Hum Genet; 2008 Jan; 72(Pt 1):35-40. PubMed ID: 17908262 [TBL] [Abstract][Full Text] [Related]
20. Prohibitin mutations are uncommon in prostate cancer families linked to chromosome 17q. White KA; Lange EM; Ray AM; Wojno KJ; Cooney KA Prostate Cancer Prostatic Dis; 2006; 9(3):298-302. PubMed ID: 16733518 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]